Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference Call on March 1
BOSTON, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today announced that management will host a conference call and webcast slide presentation on Thursday, March 1, at 4:30 p.m. ET to provide a corporate update and discuss financial results for the fourth quarter and
View HTML
Toggle Summary Ziopharm Oncology Presents Data on Very Rapid Production of CAR T Cells at Keystone Symposia Emerging Cellular Therapies: T Cells and Beyond
Human CAR+ T cells with membrane-bound IL-15 manufactured in less than two days exhibited anti-tumor activity and persistence in pre-clinical studies
View HTML
Toggle Summary Ziopharm Oncology Addresses Rumors and Stock Volatility, Affirms 2018 Guidance
BOSTON, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today responded to unfounded rumors regarding possible financing plans of the Company. Management states that it knows of no developments at the Company that would be the cause of the recent volatility and decline in
View HTML
Toggle Summary Ziopharm Oncology Provides Update on Standout Technologies during the 36th Annual J.P. Morgan Healthcare Conference
- Controlled IL-12 advancing as drug platform as monotherapy and in combination with OPDIVO ® (nivolumab) - - Non-viral T-cell platform shows potential for efficacy, scalability and cost reduction for multiple oncology targets - BOSTON, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc.
View HTML
Toggle Summary ZIOPHARM to Present at the 36th Annual J.P. Morgan Healthcare Conference
BOSTON, Dec. 21, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the 36 th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at 10 a.m. PST.
View HTML
Toggle Summary ZIOPHARM Announces Presentation of Data from T-Cell Therapy Programs at ASH Annual Meeting
— Clinical data show continued survival benefit, tumor response, and multi-year persistence of Sleeping Beauty -modified CD19-specific CAR + T cells — — Point-of-care CD19-specific CAR + T cells co-expressing mbIL15 with control switch show sustained persistence, anti-tumor effect in preclinical
View HTML
Toggle Summary ZIOPHARM Presents Positive Updated Results of Ad-RTS-hIL-12 Study in Brain Cancer at Society for Neuro-Oncology Annual Meeting
— Controlled IL-12 gene therapy turns cold tumors hot — — MRI indicates decreasing size of brain tumor lesions in several patients — — Median overall survival for patients with recurrent glioblastoma (rGBM) maintained at 12.5 months in 20mg cohort with longer follow-up — — Company conference call
View HTML
Toggle Summary ZIOPHARM Oncology to Host Conference Call on November 20, 2017 at 10:15 a.m. ET to Discuss Updated Clinical Data Presented at the 2017 Annual Meeting of the Society for Neuro-Oncology
Call to feature key neuro-oncology thought leaders
View HTML
Toggle Summary ZIOPHARM to Present at the Stifel 2017 Healthcare Conference
BOSTON, Nov. 10, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that David Mauney, M.D., CBO and interim COO, will present at the Stifel 2017 Healthcare Conference in New York on Tuesday, November 14, 2017 at 11:00 a.m. ET.
View HTML
Toggle Summary ZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities
Company to host conference call today at 4:30 p.m. ET Pivotal, randomized control trial in rGBM to initiate by end of 2017 Combination trial with checkpoint inhibitor in rGBM to initiate by end of 2017 Point-of-care trial with CAR + T cells co-expressing membrane-bound interleukin (mbIL15) to
View HTML